Anesiva Inc

Anesiva — Conference Presentation (December 2007)

52 slides from Anesiva's conference presentation, Dec 4, 2007

  1. Slide 1: Anesiva is a leader in novel products for pain management

    Anesiva is a leader in novel products for pain management. November 26, 2007 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "pla

  3. Slide 3: Focus: Approval of Pain Products

    Focus: Approval of Pain Products » Zingo Approved for children 3 – 18 yrs : August 2007 Product available for sale in 2Q08 Co-promotion & distribution with Sagent Pharmaceuticals Positive Phase 3 data in adults sNDA for adults: Submit early » Adlea Post-operative pain following orthopedic surgeries

  4. Slide 4: Pain: A Global View

    Pain: A Global View (JCAHO) $21B $19B » 1.5 billion people suffer from pain worldwide annually 50 million in U.S. » Every year in the U.S., pain results in 40 million physician office visits 4 billion lost work days $65 billion in lost work productivity » Pain is a “fifth vital sign” of patient well

  5. Slide 5: Addressing Major Pain Markets

    Addressing Major Pain Markets Efficacy Minimal Side Effects Unmet Medical Need Substantial Number of Patients Product Adlea Zingo

  6. Slide 6: Anesthesiologists: Common and Important Pain Outcomes

    Anesthesiologists: Common and Important Pain Outcomes Recall Peripheral nerve injury Recall without pain Dental injury Corneal abrasion Postdural puncture headache Neuromuscular weakness Revealing something personal IV infiltration Succynylcholine Myalgias Back pain Anxiety during MAC Discomfort fro

  7. Slide 7: Slide 7

  8. Slide 8: Product Pipeline

    Product Pipeline ZINGO™ ADLEA™ POST-SURGICAL Total Knee Replacement Bunionectomy Arthroscopic Shoulder Total Hip Replacement OSTEOARTHRITIS Knee MUSCULOSKELETAL Tendonitis NEUROPATHIC Intermetatarsal neuroma PHASE 1 PHASE 2 PHASE 3 NDA / eCTD Pediatric Adult Approved

  9. Slide 9: Zingo

    Zingo Animation (0:23 duration) Computerized animation of application of Zingo on animated patient's hand.

  10. Slide 10: Local news report on Zingo clinical trial

    (0:56 duration) Local news report describing Connecticut Children's Medical Center clinical trial of the Zingo local anesthetic product.

  11. Slide 11: Superior Product Profile

    Superior Product Profile Easily incorporated into procedure 1 – 3 minutes 0.5 mg 140 mg 12.5 mg Dose erythema, petechiae, edema erythema, blanching, edema vasoconstriction, blanching, erythema Adverse Reactions Requires 2 or more healthcare interactions Requires 2 or more healthcare interactions Log

  12. Slide 12: Positive Phase 3 Trial in Adults

    Positive Phase 3 Trial in Adults » Pain reduction demonstrated in Phase 3 trial Zingo demonstrated highly statistically significant pain reduction vs. placebo (p = 0.003) Multicenter trial of 699 adults undergoing venous access procedures Well tolerated » Submit sNDA in early 2008 to extend label to

  13. Slide 13: Zingo Manufacturing

    Zingo Manufacturing » Capacity Automated line to provide capacity of 5MM units/shift/year Multi shift capacity of 15MM/year » Automated line expected to be approved and ready for Q208 Will lower COGS (Estimated at $2.50 – $3.50 at large commercial scale) Full qualification of automated line delayed

  14. Slide 14: Zingo Market Opportunity

    Zingo Market Opportunity 174 Hospitals represents ~75% of pediatric opportunity » Hospital opportunity 18M pediatric procedures 400M adult procedures » Non-hospital opportunity >300M non-hospital procedures Stand Alone Children’s n~62 Pediatric Hospital Within Academic n~112 Other targets (adult opp

  15. Slide 15: Anesiva Commercial and Sales Teams

    Anesiva Commercial and Sales Teams » Team has extensive marketing, sales, managed markets and clinical experience » Marketing and launch of multiple blockbuster products » Extensive hospital and pain selling experience » Two highly experienced sales directors hired Broad hospital sales management ex

  16. Slide 16: Hospital Sales Process

    Hospital Sales Process 1. Create demand • Drive use among nurses 2. Gain inclusion on drug formulary • MD requests • Pharmacy conducts evaluation • Clinical • Financial (GPO contract) • Formulary committee review and vote ZINGO

  17. Slide 17: Hospital Nurses Demand Survey

    Hospital Nurses Demand Survey What Percentage of Your Pediatric Patients Would Receive Zingo? 63.2% Blood Draws 70.5% IV Placements Zingo Source: Princeton Brand Econometrics Survey of 44 Hospital-Based Nurses ZINGO

  18. Slide 18: Strategic Assessment

    Strategic Assessment Demand Creation » Market research consistently supports strong demand by nurses » Very targeted approach of 15 reps to 174 key hospitals = 75% of pediatric business » Conclusion: Anesiva can do this alone Formulary Listing » Formulary listing is rate limiting » Conclusion: Focus

  19. Slide 19: Sagent: Ideal Zingo Partner

    Sagent: Ideal Zingo Partner » Specialty pharma company developing, manufacturing, sourcing and marketing hospital products with a specific focus on injectables » Leadership team with strong industry experience Executive management team: average of >20 years industry experience and proven track recor

  20. Slide 20: Sagent and Anesiva

    Sagent and Anesiva Key selling contact for nurses Key selling contact for physicians, P&T members Conduct nursing inservices ANESIVA Complementary and Synergistic Selling Roles Anesiva + Sagent = Faster Formulary Listing + Demand Creation = Increased Sales ZINGO Key selling contact for hospital phar

  21. Slide 21: Zingo Commercial Strategies

    Zingo Commercial Strategies » Create Zingo advocates on medical and nursing staffs Develop extensive profiles of targeted hospitals with relationships established with at least one influencer » Aggressive campaign underway to: Prepare market for Zingo Ensure rapid uptake of Zingo www.manageivpain.co

  22. Slide 22: manageivpain.com

    managelVpain.com WPaln mfort Tips // Child Cases Guideline It's a little stick with a IV Insertions are one of the two most common sources of champion change pain In hospitalized children (the other Is venipuncture). Help your hospital advance its approach to managing IV pain wil be made eo How you

  23. Slide 23: a DIe

    a DIe asl The IV start can color a child’s whole hospital experience.

  24. Slide 24: Drive Parent Demand

    Drive Parent Demand » Partnering with children’s chronic disease organizations to reach parents with children who receive many IV/venipuncture procedures Cancer Diabetes Sickle Cell Hemophilia Acquired Immune Deficiency Crohn’s Congenital Hypogammaglobinemia » Objective: Raise awareness of non-pharm

  25. Slide 25: Estimated Potential Market Opportunity

    Estimated Potential Market Opportunity $100-$150 MM ~$100MM $200-250MM ? » $12-$16 pricing assumption* Targeting middle of the range Hospital segment (pediatric and adult) * Synera™ price reported to be $12.60. EMLA price reported to be $8.34. ZINGO Adult hospital Children hospital + = + Non-hospita

  26. Slide 26: Partnering Plans

    Partnering Plans » Seeking partner to market Zingo ex-U.S. Early discussions with potential partners indicate market size in Europe similar to U.S. Canada » Will seek partner to market Zingo for outpatient settings Pediatrician offices Oncology clinics IV placements Hemodialysis Dermatology ZINGO

  27. Slide 27: Extensive Out-Licensing Opportunities

    Extensive Out-Licensing Opportunities Salmon calcitonin Insulin Human growth hormone Beta interferon Erythropoietin Follicle stimulating hormone Pegylated alpha interferon ZINGO » Rights to Powderject technology divided between Anesiva and Pfizer Anesiva: powder forms of medications except vaccines

  28. Slide 28: ADLEA: Rapid, Long Lasting, Non-opioid Analgesic

    ADLEA™ Rapid, Long Lasting, Non-opioid Analgesic

  29. Slide 29: Unique Mechanism of Action

    Unique Mechanism of Action Adlea: a TRPV1 agonist based on capsaicin TRPV1 » Long-lasting “ noxious pain ” transmitted by C neurons Dull, aching, throbbing, burning pain Immediate “ adaptive pain ” (< 1 second) pain transmitted by A neurons » Single administration degrades TRPV1 receptor providing p

  30. Slide 30: Local news report on Adlea

    (2:13 duration) Local news report on the use of Adlea in post-operative pain management.

  31. Slide 31: Superior Product Profile

    8-12 weeks Rapid LOW Transient pain on injection with non-surgical procedures Single app. for post-surgical Every 8-12 wks for OA of knee +++ Adlea (Based on currently completed studies) Superior Product Profile HIGH Respiratory depression, nausea, vomiting Rapid 4-48 Hours Frequent +++ Opioids HIGH

  32. Slide 32: Market Opportunities

    Market Opportunities 216,000 Interdigital (Morton’s) Neuroma Post-Trauma 700,000 Bunionectomy 1.25 MM Tendonitis of the Elbow 5 MM Osteoarthritis of the Knee Musculoskeletal 250,000 Total Hip Replacement 485,000 Arthroscopic Shoulder Surgery 473,000 Total Knee Replacement 56.7 MM Post-Surgical Annua

  33. Slide 33: Success in Multiple Clinical Settings

    Post- surgical Neuro Musculo- skeletal Results* Indication Phase Success in Multiple Clinical Settings Reduction in pain and improvement in WOMAC scores (p < 0.001) over 8 weeks Moderate Knee Osteoarthritis Reduction in pain of 63% at 4 weeks vs. placebo (p=0.0188) Interdigital Neuroma Reduction in

  34. Slide 34: Clinical Pathway Defined

    Clinical Pathway Defined Two pivotal Phase 3 trials for NDA to begin in 1H08 Total knee replacement surgeries Bunionectomy surgeries » Will seek two indications Post-surgical pain associated with orthopedic procedures Osteoarthritis » » Bunionectomy benefits Strong efficacy data already exists Faste

  35. Slide 35: Clinical Overview: Surgical Studies

    Clinical Overview: Surgical Studies Phase 3 Phase 2 Teaches surgeons about Adlea in a variety of clinical settings 1. Major joints and/or common orthopedic procedures: knee, hip, shoulder 2. Different administrations: instillation/withdrawal in open surgical wound, injection/no withdrawal in arthros

  36. Slide 36: Unmet Need in TKA

    Unmet Need in TKA » TKA and its subsequent rehabilitation is extremely painful for patients Skin and muscle incision and cutting of bone Intensive and lengthy rehabilitation begins immediately after surgery to ensure good outcomes Despite using standard pain treatments, patients still experience sig

  37. Slide 37: Knee Replacement Surgery Phase 2 Study

    Knee Replacement Surgery Phase 2 Study » Double-blind, placebo-controlled trial in 50 patients undergoing total knee arthroplasty Randomized 1:1 between Adlea and placebo Single administration of Adlea instilled into surgical site prior to closure » Efficacy endpoints achieved despite significant co

  38. Slide 38: Knee Replacement Surgery Phase 2 Study

    Knee Replacement Surgery Phase 2 Study ADLEA Postoperative Day Placebo plus concomitant anesthesia and analgesia p = 0.027 p = 0.039 Adlea plus concomitant anesthesia and analgesia

  39. Slide 39: Extended Benefit Despite Low Exposure

    Extended Benefit Despite Low Exposure » Unlike other pain medications, Adlea provides long-term pain relief based on MOA, not pharmacokinetic properties » Limited and short systemic exposure supports good safety profile ADLEA Mean Plasma Concentration

  40. Slide 40: Bunionectomy Dose-ranging Study

    Bunionectomy Dose-ranging Study • Reduced post-surgical pain and use of rescue medication in dose- dependent fashion • No side effects observed » Bunionectomy patients received 100, 500 or 1,000 µg into wound pre- closure » n = 182 » Numeric Rating Scale (“NRS”) scored pain » Assessed rescue medicat

  41. Slide 41: Osteoarthritis of the Knee

    Osteoarthritis of the Knee » ~5 million U.S. patients suffer from moderate to severe OA of the knee Expected to grow due to aging of the population » Pain from end-stage OA of the knee is intractable and debilitating Patients are likely to eventually require total knee arthroplasty » 20-40% of patie

  42. Slide 42: Development Path for OA of the Knee

    Development Path for OA of the Knee » Preclinical Low systemic exposure Adlea not a chronic drug No 2-year carcinogenicity study (3 years start to finish) » Clinical plan agreed upon by FDA Small safety database for approval: 1,000 patients—small compared to thousands required for some recent OA dru

  43. Slide 43: Six Week Duration of Action for End-stage Knee Osteoarthritis

    Six Week Duration of Action for End-stage Knee Osteoarthritis • Reduced pain 50%-60% • Efficacy for at least six weeks • Transient pain on injection » Patients scheduled for surgery within 6 weeks of drug administration » Single injection of Adlea (1000 µg) or placebo into knee joint 10 minutes afte

  44. Slide 44: Phase 2 Study in Moderate OA

    Phase 2 Study in Moderate OA Highly statistically significant (p<0.001) reduction in WOMAC Question #1 (pain walking on flat surface) at weeks 1 through 8 in 1000 µg stepped dose Large reductions in WOMAC total score from baseline lasting through week 8 for all groups Reductions in WOMAC subscales (

  45. Slide 45: Osteoarthritis: Follow Up Data

    Osteoarthritis: 12 Week Follow Up Data Benefit of single Adlea treatment persists for up to 12 weeks Weeks Following Adlea Treatment 65% 64% 61% - Percentage Reduction from Baseline 0.74 0.79 0.86 2.22 Average Pain Score n=50 n=54 n=51 Baseline n=54 ADLEA

  46. Slide 46: CORPORATE

    CORPORATE

  47. Slide 47: Experienced Team

    Experienced Team John P. McLaughlin CEO Nancy E. Donahue Sr. VP, Sales & Marketing James Carr, PharmD VP, Marketing Joseph Levato Director, Sales David Randall Director, Sales Peony Yu, M.D. VP, Clinical Research Shaun Comfort, M.D. Senior Director, Clinical Research Jack Regan Sr. VP, Operations Yv

  48. Slide 48: Patent Protection

    Patent Protection » Zingo™ License approximately 150 patents and applications on methods and apparatus for delivering powder forms of medication Principal patents expire in 2014 » Adlea™ Own or license approximately 15 patents and applications relating to capsaicin technology, compounds and their ap

  49. Slide 49: Strong cash position

    Strong cash position » Cash position of $54.5 MM as of September 30, 2007 Sufficient cash to fund activities into 2008 » Financial guidance for 2007 Net loss for FY07: $50MM - $55MM before non-cash stock compensation of approximately $9.0MM Cash, cash equivalents and short term investments at end of

  50. Slide 50: Key Milestones

    Key Milestones Conduct Phase 3 trial in bunionectomy surgeries Submit filing for product approval in adult indication Approval of NDA / eCTD for pediatric indication In process Conduct Phase 2/3 trial in OA of the knee Conduct Phase 2 trial in TKA surgeries using higher dose Conduct Phase 3 trial in

  51. Slide 51: Anesiva Investment Summary

    Anesiva Investment Summary » Late stage product portfolio Zingo: Approved Adlea: Blockbuster potential in growing markets Powerful, long-acting analgesic without opioid-like side effects » Lower risk approach » Addressing large, underserved markets » Compelling valuation » Near-term news flow NASDAQ

  52. Slide 52: Anesiva is a leader in novel products for pain management

    Anesiva is a leader in novel products for pain management. Please visit www.Anesiva.com to learn more. Nasdaq: ANSV

Anesiva — Conference Presentation (December 2007) on 6ix